Anavex Life Sciences Reports Net Income of $7.8 Million in Q3 Fiscal 2026

Anavex Life Sciences Corp. reported a significant turnaround in its financial performance for the third quarter of fiscal 2026, ending June 30, with a net income of $7.8 million, or $0.08 per share, compared to a net loss of $13.2 million, or $0.16 per share, for the same period in the previous year. This improvement is largely attributed to a reversal of stock-based compensation expenses totaling $15.5 million, primarily linked to the termination of the former CEO. Total operating expenses decreased to $6.7 million from $14.5 million year-over-year, reflecting a substantial reduction in research and development costs, which fell to $4.7 million from $10 million.

For the nine months ended June 30, 2026, Anavex reported a net loss of $3.2 million, or $0.03 per share, a significant decrease from a loss of $36.6 million, or $0.43 per share, in the prior year. The total operating expenses for this period were $6.5 million, down from $40.6 million, again primarily due to the reversal of stock-based compensation expenses. The company’s cash and cash equivalents increased to $118.3 million from $102.6 million as of September 30, 2025, bolstered by net proceeds of $36.4 million from the issuance of common stock under a sales agreement.

Strategically, Anavex is focusing on advancing its lead compound, ANAVEX 2-73 (blarcamesine), for the treatment of mild cognitive impairment due to Alzheimer’s disease and other neurodevelopmental disorders. The company has paused development on other assets, including ANAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066, pending additional funding or strategic partnerships. The company is also engaging with the U.S. Food and Drug Administration (FDA) to align on a regulatory and clinical development strategy for ANAVEX 2-73.

Operationally, Anavex has made significant changes in its leadership, including the termination of its former CEO, which has led to a reassessment of its internal controls and disclosure procedures. The company has acknowledged material weaknesses in its internal controls over financial reporting and is implementing remediation measures. As of June 30, 2026, Anavex had 92,696,842 shares of common stock outstanding, reflecting an increase from the previous fiscal year.

Looking ahead, Anavex expects to continue utilizing its capital resources to advance the clinical development of ANAVEX 2-73. The company anticipates that its current cash balance will support operations and planned development activities until mid to late fiscal 2028. However, it also recognizes the need for substantial additional capital to fund ongoing research and development efforts, and it may seek to raise funds through equity or debt financing, which could impact shareholder ownership.